1. Special types of breast cancer: Clinical, Histological Features and Survival Outcomes.
- Author
-
Erdiş, Eda, Yılmaz, Mukaddes, Uçar, Mahmut, Demir, Necla, Alandağ, Celal, and Yücel, Birsen
- Subjects
- *
LUMPECTOMY , *PROGESTERONE receptors , *ADJUVANT chemotherapy , *OVERALL survival , *CARCINOMA - Abstract
Objective: In this study, we investigated the clinical characteristics and survival outcomes of patients diagnosed with special types of breast cancer who presented to our clinic. Methods: The demographic, clinicopathological, and survival characteristics of all rare, histologically special subtype breast cancer patients who applied to Sivas Cumhuriyet University Oncology Center between 2010 and 2020 were retrospectively reviewed. Results: The records of 1198 patients with invasive breast cancer were examined, and 104 of them (8%) were identified as having other histological special subtypes. Of these, 19 (8%) had apocrine cancer, 19 (8%) had mucinous type, 17 (7%) had invasive cribriform, 15 (6%) had invasive papillary, 11 (4%) had metaplastic type, 9 (4%) had invasive micropapillary, 6 (2%) had neuroendocrine, 3 (1%) had tubular type, 3 (1%) had microinvasive type, and 2 (1%) had undifferentiated carcinoma. The majority of these patients, 102 (98%), were female, with a median age of 52 years (range 26-82). Of the women, 60 (59%) were postmenopausal, and 42 (41%) were premenopausal. The ECOG Performance Score (PS) was 0 in 79 (76%) patients, 1 in 17 (16%) patients, and 2 in 8 (8%) patients. Upon evaluation, 50 patients (48%) had comorbid conditions, and 26 patients (25%) had a family history of breast cancer. At diagnosis, 25 patients (24%) were stage I, 50 (48%) were stage II, 26 (25%) were stage III, and 3 (3%) were stage IV. Histopathologically, 75 patients (72%) were estrogen receptor (ER)-positive, 69 (66%) were progesterone receptor (PR)-positive, and 26 (25%) were HER2-positive. An intraductal component was detected in 54 (60%) patients, and multicentricity was observed in 15 (16%) patients. A modified radical mastectomy was performed on 56 (54%) patients, while breast-conserving surgery was performed on 45 (43%) patients. Adjuvant chemotherapy was administered to 76 (73%) patients, hormonal therapy to 73 (70%), and radiotherapy to 72 (68%). The median follow-up period was 54 months (range 1-201). During follow-up, metastasis was detected in 13 patients (13%), and recurrence was detected in 7 patients (7%). The 5-year and 10-year overall survival rates were 86% and 77%, respectively, while the 5-year and 10-year event-free survival rates were 79% and 70%, respectively. Conclusion: In our study, the majority of patients with special type breast carcinoma were non-metastatic, and histopathologically, they were hormone receptor-positive with low grade. There was no statistically significant difference in 5-year and 10-year overall survival or event-free survival among the pecial types. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF